November 16, 2016
Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 16, 2016--
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of
James R. Meyers to Executive Vice President, Worldwide Commercial
Operations, with responsibility for commercial operations in North
America, Europe and Japan. Mr. Meyers will become an officer of the
company and member of Gilead’s senior leadership team.
Mr. Meyers joined Gilead in 1996 as a regional sales director and has
been the Senior Vice President of North American Commercial Operations
since 2007. In his 20 years at Gilead, Mr. Meyers has been instrumental
in building out the company’s commercial operations in North America,
including leading successful product launches in HIV, oncology,
cardiovascular, respiratory and liver diseases. Prior to Gilead, Mr.
Meyers held positions of increasing responsibility in sales, training,
marketing and management with Zeneca Pharmaceuticals and Astra USA. He
received his Bachelor's degree in economics from Boston College.
“Jim has demonstrated a remarkable ability to navigate the complexities
of commercial operations, ensuring we reach diverse audiences with
information about Gilead’s medicines and ultimately that we make those
medicines accessible to people in need,” said Kevin Young CBE, Chief
Operating Officer, Gilead Sciences. “I am confident that as Gilead’s
portfolio of products continues to grow, Jim’s leadership and
exceptional track record make him ideally suited to lead our global
commercial organization.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2016, as filed
with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
statements.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161116006551/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
Media
Amy
Flood, 650-522-5643
